AngioDynamics Expands European Indications for NanoKnife System
AngioDynamics has expanded the indications for its NanoKnife system throughout Europe to incorporate gentle tissue ablation for tumors within the liver, kidneys, prostate and pancreas, together with use in sufferers with intermediate-risk prostate most cancers.
This improvement expands entry to the system’s irreversible electroporation (IRE) know-how for physicians coping with tumors which can be tough to take away or are situated near crucial constructions.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
The answer makes use of non-thermal IRE ablation to destroy tumor cells whereas preserving surrounding anatomy resembling blood vessels, nerves and bile ducts. This mechanism of motion is effectively suited to tumors in anatomically advanced areas such because the liver and pancreas.
Medical analysis demonstrates the procedural feasibility of IRE know-how in numerous stable tumor contexts, together with hepatocellular carcinoma, metastatic colorectal most cancers, and renal tumors.
Each potential research and real-world analyzes proceed to validate the security profile and advance the scientific utility of IRE for difficult anatomic illness states.
To facilitate additional scientific acceptance and proof improvement, AngioDynamics will launch the LIVER-IRE World Registry in collaboration with Professor Ajith Siriwardena from the College of Manchester.
The registry will prospectively assess outcomes in sufferers receiving IRE remedy for liver tumors, enriching real-world knowledge on multi-organ functions of the NanoKnife System.
AngioDynamics senior vice chairman and cardiovascular and worldwide common supervisor Laura Piccinini stated: “NanoKnife prostate continues to realize scientific traction, and we stay dedicated to advancing that indication globally.
“The growth of further organ indications in Europe underlines the broader potential of IRE know-how and strengthens NanoKnife as a scalable platform for advanced tumor ablation. Our aim is to make sure physicians have entry to differentiated instruments that broaden remedy choices for sufferers throughout a number of illness states.”
In October 2024, AngioDynamics collaborated with College School London Hospital (UCLH) in the UK to provoke a potential registry examine on the long-term results of the NanoKnife System within the remedy of intermediate-risk unifocal prostate most cancers.
